Continuum Rabies

This page contains information on Continuum Rabies for veterinary use.
The information provided typically includes the following:
  • Continuum Rabies Indications
  • Warnings and cautions for Continuum Rabies
  • Direction and dosage information for Continuum Rabies

Continuum Rabies

This treatment applies to the following species:
Manufacturer: Intervet/Merck Animal Health

Rabies Vaccine

Killed Virus

Product Description: Continuum® Rabies Is An Inactivated Virus Vaccine Produced From The Highly Immunogenic Pasteur Rabies Virus Strain. continuum® Rabies Contains An Adjuvant To Enhance Long-lasting Immunity And Is Presented In A Ready-to-use Liquid Form.

indications

For the vaccination of healthy dogs as an aid in the prevention of disease caused by rabies for 3 years following initial and booster vaccinations.

For the vaccination of healthy cats as an aid in prevention of disease caused by rabies for 4 years following initial and booster vaccinations.

Safety Data

CONTINUUM® Rabies was demonstrated to be > 94% reaction-free when administered to dogs and > 98% reaction-free when administered to cats of various ages, breeds, and sexes.

Dog Efficacy Data

Sixty-four seronegative pups were randomly assigned to two groups: Group 1 contained 33 pups and group 2 contained 31 pups. Pups in group 1 were vaccinated once at 12 weeks of age with CONTINUUM® Rabies. Pups in group 2 were nonvaccinated control dogs. Dogs were held in strict isolation for 3 years (36 months) following vaccination prior to being challenged with virulent rabies virus. The geometric mean RFFIT antibody titers remained at high levels throughout the isolation period.

Table 1. Geometric mean RFFIT titers in dogs following vaccination

Virus Fraction (Assay)

Pre-vac

Months After Vaccination

1

3

6

9

12

18

24

30

36

Rabies (RFFIT)

< 5

376

130

122

143

174

205

106

63

115

At 36 months post vaccination, the GMT for rabies was 115. Thirty-six months following vaccination, dogs were challenged with virulent rabies virus (New York City Street Virus, masseter muscle challenge). The 31 age-matched, nonvaccinated control dogs were also challenged at that time.

Following challenge with virulent rabies, 30 of the 31 controls and 1 of the 33 vaccinates developed signs typical of rabies, including excessive salivation, urination, anorexia, dysphagia, depression, paralysis, aggression, coma, and death. Rabies infection status was confirmed using fluorescent antibody (FA) testing of brain tissue. Clinical signs of rabies were prevented in 97% of vaccinated dogs, whereas 97% of control dogs were infected, exceeding the USDA requirements of 80% for rabies vaccine efficacy studies.

Table 2. Rabies Challenge - Dogs

treatment

Dogs

# Surviving Challenge

Fluorescent Antibody Positive

Continuum® Rabies

33

32 (97%)

1

Control

31

1 (3%)

30

The results of this study demonstrate CONTINUUM® Rabies provides protection against virulent rabies challenges in 12 weeks-of-age or older dogs for 3 years following vaccination.

Cat Efficacy Data

Forty seronegative kittens were randomly assigned to two groups. Group 1 contained 25 kittens and group 2 contained 15 kittens. Kittens in group 1 were vaccinated once at 12 weeks of age with CONTINUUM® Rabies. Kittens in group 2 were nonvaccinated control cats. Cats were held in strict isolation for 4 years (48 months) following the last vaccination prior to being challenged with virulent rabies virus. The geometric mean antibody titers (GMT) remained at high levels throughout the isolation period.

Table 3. Geometric Mean Rffit Titers In Cats Following Vaccination

virus Fraction (assay)

Pre-vac

Months After Vaccination

1

3

6

9

12

18

24

30

36

42

48

Rabies (RFFIT)

< 5

608

469

489

482

503

512

501

450

548

410

412

At 48 months post vaccination, the GMT for rabies was 412. Fifty months following vaccination, cats were challenged with virulent rabies virus (New York City Street Virus, intramuscular challenge). The 15 age-matched, nonvaccinated control cats were also challenged at that time.

Following challenge with virulent rabies, 14 of the 15 controls and none of the 25 vaccinates developed signs typical of rabies, including excessive salivation, urination, anorexia, dysphagia, depression, paralysis, aggression, coma, and death. Rabies infection status was confirmed using fluorescent antibody (FA) testing of brain tissue. Clinical signs of rabies were prevented in 100% of vaccinated cats, whereas 93% of control cats were infected, exceeding the USDA requirements of 80% for rabies vaccine efficacy studies.

Table 4. Rabies Challenge - Cats

treatment

Cats

# Surviving Challenge

Fluorescent Antibody Positive

Continuum® Rabies

25

25 (100%)

0

Control

15

1 (7%)

14

The results of this study demonstrate CONTINUUM® Rabies provides protection against virulent rabies challenges in 12 weeks-of-age or older cats for 4 years following vaccination.

Directions For Use: Dogs

Aseptically administer 1 mL by the subcutaneous route. Initial vaccination of healthy dogs may be given as early as 12 weeks of age, with a booster injection for rabies using CONTINUUM® Rabies or CONTINUUM® DAP-R administered 1 year later. Revaccinate every three years thereafter with a single dose of CONTINUUM® Rabies or CONTINUUM® DAP-R.

Cats

Aseptically administer 1 mL by the subcutaneous route. Initial vaccination of healthy cats may be given as early as 12 weeks of age, with a booster injection for rabies using CONTINUUM® Rabies or CONTINUUM® FELINE HCP-R administered 1 year later. Revaccinate every four years thereafter with a single dose of CONTINUUM® Rabies or CONTINUUM® FELINE HCP-R. Revaccination should be in accordance with local or state regulations.

Precautions

1. Recommended storage temperature 35-45°F (2-7°C). Do not freeze.

2. Shake well before use.

3. Non-chemically sterilized needles and syringes should be used for administration of vaccine.

4. Administration of epinephrine may be indicated in the event of an anaphylactic reaction.

5. Contains neomycin, polymyxin B, and thimerosal as preservatives.

6. Burn this container and all unused contents.

7. Only healthy animals should be vaccinated. Animals incubating any disease or animals stressed due to shipping, malnutrition, or parasitism may not achieve or maintain an adequate immune response.

8. The vaccine contains a pH indicator as an added feature. If the rabies vaccine changes in color from red to orange to yellow, do not use.

9. This product is not hazardous when used according to directions supplied. A material safety data sheet (MSDS) is available upon request. This and any other consumer information can be obtained by calling Intervet’s Customer Service Department at 1-800-441-8272.

Supplied

Cartons of 25 1-dose/1-mL vials. Packaged in recyclable plastic containers.

Sales Product Code No.

006770

For Veterinary Use Only

U.s. Veterinary License No. 165a

Intervet Inc., Millsboro, De 19966

Www.continuum3.com

1-800-441-8272

Rev. 045502

Nac No.

10474531
INTERVET INC., MERCK ANIMAL HEALTH
556 MORRIS AVE., SUMMIT, NJ, 07901
Telephone:   862-245-4321
Order Desk:   800-648-2118
Fax:   862-245-4935
Customer Service:   800-521-5767
Website:   www.intervet.com
Every effort has been made to ensure the accuracy of the Continuum Rabies information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-09-05

(web5)